Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis
Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis.
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07602-0 |
| _version_ | 1818198286801043456 |
|---|---|
| author | Xiaoyun Hu Rong Li Qi Li Mengya Zang Guosheng Yuan Jinzhang Chen |
| author_facet | Xiaoyun Hu Rong Li Qi Li Mengya Zang Guosheng Yuan Jinzhang Chen |
| author_sort | Xiaoyun Hu |
| collection | DOAJ |
| description | Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis. |
| first_indexed | 2024-12-12T02:03:28Z |
| format | Article |
| id | doaj.art-f2cb7053080949dc87d5066299cb2822 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-12T02:03:28Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-f2cb7053080949dc87d5066299cb28222022-12-22T00:42:07ZengBMCBMC Infectious Diseases1471-23342022-07-012211910.1186/s12879-022-07602-0Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxisXiaoyun Hu0Rong Li1Qi Li2Mengya Zang3Guosheng Yuan4Jinzhang Chen5Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityDepartment of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical UniversityKey points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis.https://doi.org/10.1186/s12879-022-07602-0Hepatocellular carcinoma (HCC)Hepatitis B virus (HBV)Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)ReactivationTenofovir alafenamide fumarate (TAF) |
| spellingShingle | Xiaoyun Hu Rong Li Qi Li Mengya Zang Guosheng Yuan Jinzhang Chen Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis BMC Infectious Diseases Hepatocellular carcinoma (HCC) Hepatitis B virus (HBV) Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) Reactivation Tenofovir alafenamide fumarate (TAF) |
| title | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis |
| title_full | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis |
| title_fullStr | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis |
| title_full_unstemmed | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis |
| title_short | Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis |
| title_sort | interaction between baseline hbv loads and the prognosis of patients with hcc receiving anti pd 1 in combination with antiangiogenic therapy undergoing concurrent taf prophylaxis |
| topic | Hepatocellular carcinoma (HCC) Hepatitis B virus (HBV) Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) Reactivation Tenofovir alafenamide fumarate (TAF) |
| url | https://doi.org/10.1186/s12879-022-07602-0 |
| work_keys_str_mv | AT xiaoyunhu interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis AT rongli interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis AT qili interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis AT mengyazang interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis AT guoshengyuan interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis AT jinzhangchen interactionbetweenbaselinehbvloadsandtheprognosisofpatientswithhccreceivingantipd1incombinationwithantiangiogenictherapyundergoingconcurrenttafprophylaxis |